Tags

Type your tag names separated by a space and hit enter

Mismatch Repair Deficiency in Endometrial Cancer: Immunohistochemistry Staining and Clinical Implications.
Appl Immunohistochem Mol Morphol. 2019 10; 27(9):678-682.AI

Abstract

INTRODUCTION

DNA mismatch repair (MMR) deficiency is associated with increased risk of developing several types of cancer and is the most common cause of hereditary endometrial cancer. Identification of the microsatellite instability (MSI) phenotype in endometrial carcinoma is important given that such tumors are frequent.

OBJECTIVE

The objective of this study was to assess the utility of immunohistochemistry (IHC), a simple and fast technique, in detecting MSI status in endometrial carcinoma and evaluate the correlation between the MSI phenotype and the various anatomo-clinical parameters.

METHODS

IHC expression of 4 markers (MLH1, MSH2, PMS2, and MSH6) was studied. For all IHC markers, a combined score based on the intensity of nuclear labeling and the percentage of labeled cells was defined to establish a score. Correlation between MSI phenotype and different clinicopathologic parameters was evaluated using statistical analysis (software STATA and the Fisher exact test).

RESULTS

The mean age of the patients was 58.6 years. Positive staining was highly extended (score 3) with 79% to 100% of marked cells. Less than 10% of positive tumor cells were seen in 3% of cases for MSH6 and PMS2. Abnormal MMR IHC was detected in 10 cases (22.22%). Seven tumors showed loss of MLH1/PMS2. The loss of MSH2/MSH6 was observed in 1 case. The loss of MLH1 or PMS2 was seen only in 2 cases. The number of MSI positive status was 10 cases (22.7%). Correlation between clinicopathologic parameters showed MMR deficiency was significantly associated with low-grade tumor and localized stage. There was no positive correlation between age, histologic subtype, or myometrium invasion.

CONCLUSIONS

In summary, detection of DNA MMR deficiencies by IHC can effectively diagnose the MSI phenotype in endometrial carcinoma. Correlation between clinicopathologic parameters showed MMR deficiency was significantly associated with low-grade tumor and localized stage.

Authors+Show Affiliations

Department of Pathology, Salah Azeiz Institute, Tunis, Tunisia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31567138

Citation

Doghri, Raoudha, et al. "Mismatch Repair Deficiency in Endometrial Cancer: Immunohistochemistry Staining and Clinical Implications." Applied Immunohistochemistry & Molecular Morphology : AIMM, vol. 27, no. 9, 2019, pp. 678-682.
Doghri R, Houcine Y, Boujelbène N, et al. Mismatch Repair Deficiency in Endometrial Cancer: Immunohistochemistry Staining and Clinical Implications. Appl Immunohistochem Mol Morphol. 2019;27(9):678-682.
Doghri, R., Houcine, Y., Boujelbène, N., Driss, M., Charfi, L., Abbes, I., Mrad, K., & Sellami, R. (2019). Mismatch Repair Deficiency in Endometrial Cancer: Immunohistochemistry Staining and Clinical Implications. Applied Immunohistochemistry & Molecular Morphology : AIMM, 27(9), 678-682. https://doi.org/10.1097/PAI.0000000000000641
Doghri R, et al. Mismatch Repair Deficiency in Endometrial Cancer: Immunohistochemistry Staining and Clinical Implications. Appl Immunohistochem Mol Morphol. 2019;27(9):678-682. PubMed PMID: 31567138.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mismatch Repair Deficiency in Endometrial Cancer: Immunohistochemistry Staining and Clinical Implications. AU - Doghri,Raoudha, AU - Houcine,Yoldez, AU - Boujelbène,Nadia, AU - Driss,Maha, AU - Charfi,Lamia, AU - Abbes,Imène, AU - Mrad,Karima, AU - Sellami,Rim, PY - 2019/10/1/pubmed PY - 2020/6/20/medline PY - 2019/10/1/entrez SP - 678 EP - 682 JF - Applied immunohistochemistry & molecular morphology : AIMM JO - Appl Immunohistochem Mol Morphol VL - 27 IS - 9 N2 - INTRODUCTION: DNA mismatch repair (MMR) deficiency is associated with increased risk of developing several types of cancer and is the most common cause of hereditary endometrial cancer. Identification of the microsatellite instability (MSI) phenotype in endometrial carcinoma is important given that such tumors are frequent. OBJECTIVE: The objective of this study was to assess the utility of immunohistochemistry (IHC), a simple and fast technique, in detecting MSI status in endometrial carcinoma and evaluate the correlation between the MSI phenotype and the various anatomo-clinical parameters. METHODS: IHC expression of 4 markers (MLH1, MSH2, PMS2, and MSH6) was studied. For all IHC markers, a combined score based on the intensity of nuclear labeling and the percentage of labeled cells was defined to establish a score. Correlation between MSI phenotype and different clinicopathologic parameters was evaluated using statistical analysis (software STATA and the Fisher exact test). RESULTS: The mean age of the patients was 58.6 years. Positive staining was highly extended (score 3) with 79% to 100% of marked cells. Less than 10% of positive tumor cells were seen in 3% of cases for MSH6 and PMS2. Abnormal MMR IHC was detected in 10 cases (22.22%). Seven tumors showed loss of MLH1/PMS2. The loss of MSH2/MSH6 was observed in 1 case. The loss of MLH1 or PMS2 was seen only in 2 cases. The number of MSI positive status was 10 cases (22.7%). Correlation between clinicopathologic parameters showed MMR deficiency was significantly associated with low-grade tumor and localized stage. There was no positive correlation between age, histologic subtype, or myometrium invasion. CONCLUSIONS: In summary, detection of DNA MMR deficiencies by IHC can effectively diagnose the MSI phenotype in endometrial carcinoma. Correlation between clinicopathologic parameters showed MMR deficiency was significantly associated with low-grade tumor and localized stage. SN - 1533-4058 UR - https://www.unboundmedicine.com/medline/citation/31567138/Mismatch_Repair_Deficiency_in_Endometrial_Cancer:_Immunohistochemistry_Staining_and_Clinical_Implications_ L2 - https://doi.org/10.1097/PAI.0000000000000641 DB - PRIME DP - Unbound Medicine ER -